Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Rating of "Moderate Buy" by Brokerages

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) have earned an average rating of "Moderate Buy" from the seven ratings firms that are presently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $16.50.

A number of analysts have commented on NMRA shares. JPMorgan Chase & Co. lowered Neumora Therapeutics from an "overweight" rating to a "neutral" rating and decreased their price objective for the stock from $18.00 to $15.00 in a report on Tuesday, November 5th. Royal Bank of Canada cut Neumora Therapeutics from an "outperform" rating to a "sector perform" rating and dropped their price objective for the company from $29.00 to $4.00 in a research note on Thursday, January 2nd. Needham & Company LLC reiterated a "buy" rating and issued a $23.00 target price on shares of Neumora Therapeutics in a research note on Thursday, January 2nd. William Blair restated an "outperform" rating on shares of Neumora Therapeutics in a report on Wednesday, January 15th. Finally, Bank of America decreased their price objective on shares of Neumora Therapeutics from $22.00 to $7.00 and set a "buy" rating for the company in a research note on Monday, January 6th.

Neumora Therapeutics Trading Up 0.8 %

NMRA stock traded up $0.02 during trading on Monday, reaching $1.95. 228,626 shares of the stock were exchanged, compared to its average volume of 7,304,534. Neumora Therapeutics has a twelve month low of $1.83 and a twelve month high of $21.00. The firm's 50 day moving average is $7.08 and its 200 day moving average is $10.53. The firm has a market cap of $314.23 million, a P/E ratio of -1.04 and a beta of 2.71.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.06). During the same period in the prior year, the company posted ($1.14) earnings per share. As a group, analysts predict that Neumora Therapeutics will post -1.61 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Neumora Therapeutics

Several large investors have recently modified their holdings of NMRA. Geode Capital Management LLC increased its stake in shares of Neumora Therapeutics by 54.0% in the third quarter. Geode Capital Management LLC now owns 1,979,847 shares of the company's stock worth $26,159,000 after purchasing an additional 694,385 shares in the last quarter. State Street Corp raised its stake in shares of Neumora Therapeutics by 65.3% during the 3rd quarter. State Street Corp now owns 1,790,707 shares of the company's stock valued at $23,655,000 after purchasing an additional 707,409 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in Neumora Therapeutics by 139.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 698,255 shares of the company's stock worth $9,224,000 after purchasing an additional 406,891 shares during the period. Auour Investments LLC bought a new stake in shares of Neumora Therapeutics during the third quarter valued at about $3,302,000. Finally, Cerity Partners LLC bought a new position in shares of Neumora Therapeutics in the third quarter valued at approximately $3,209,000. Hedge funds and other institutional investors own 47.65% of the company's stock.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.